--- title: "Glaukos | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 185.61 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/294255852.md" datetime: "2026-07-29T20:22:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294255852.md) - [en](https://longbridge.com/en/news/294255852.md) - [zh-HK](https://longbridge.com/zh-HK/news/294255852.md) generator: "portal-rs" --- # Glaukos | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 185.61 M Revenue: As of FY2026 Q2, the actual value is USD 185.61 M, beating the estimate of USD 150.91 M. EPS: As of FY2026 Q2, the actual value is USD -0.31, missing the estimate of USD -0.2889. EBIT: As of FY2026 Q2, the actual value is USD -16.26 M. ### Cash Position Glaukos Corporation ended the second quarter of 2026 with approximately $289.3 million in cash and cash equivalents, short-term investments, and restricted cash, and no debt. As of June 30, 2026, cash and cash equivalents were $114.485 million, short-term investments were $171.741 million, and restricted cash was $3.115 million. This total cash, cash equivalents, short-term investments, and restricted cash increased from $280.5 million as of March 31, 2026. Cash and cash equivalents as of June 30, 2026, were $114.485 million, compared to $90.813 million as of December 31, 2025. ### Segment Revenue Glaukos Corporation reported record net sales for the second quarter ended June 30, 2026, of $185.6 million, an increase of 50% year-over-year on a reported basis and 49% on a constant currency basis compared to $124.1 million in Q2 2025. - **Glaucoma Sales:** Glaucoma net sales reached $155.2 million in Q2 2026, up 50% year-over-year. - **U.S. Glaucoma Sales:** U.S. Glaucoma net sales were $118.5 million in Q2 2026, marking a 64% increase year-over-year, with iDose® TR sales contributing approximately $74 million. - **International Glaucoma Sales:** International Glaucoma sales were $36.631 million in Q2 2026, compared to $31.251 million in Q2 2025, representing a 17.2% reported year-over-year increase, 16.4% operational growth, and 0.8% currency impact. This was also reported as approximately $36.6 million, with 17% year-over-year growth on a reported basis and 16% on a constant currency basis. - **Corneal Health Sales:** Corneal Health net revenues were approximately $30.4 million in Q2 2026, reflecting a 48% year-over-year growth, including Epioxa® net sales of approximately $11 million. Year-to-date total net sales for Q2 2026 were $336.181 million, compared to $230.784 million for the same period in 2025. ### Gross Margin - **GAAP Gross Margin:** For Q2 2026, GAAP gross margin was approximately 82% ($151,594 thousand), up from approximately 78% ($97,224 thousand) in Q2 2025. Year-to-date GAAP gross margin for Q2 2026 was 80.0%. - **Non-GAAP Gross Margin:** For Q2 2026, Non-GAAP gross margin was approximately 85%, compared to approximately 83% in Q2 2025. Year-to-date Non-GAAP gross margin for Q2 2026 was 84.1%. ### Operating Expenses - **Total Operating Expenses (GAAP):** Total operating expenses were $168.861 million in Q2 2026, compared to $119.913 million in Q2 2025. For the year-to-date, total operating expenses were $305.949 million in 2026, compared to $222.939 million in 2025. - **Total Operating Expenses (Non-GAAP):** Total operating expenses were $163.0 million in Q2 2026, up 36% from $119.6 million in Q2 2025. - **Selling, General and Administrative (SG&A) Expenses:** - **GAAP SG&A:** SG&A expenses in Q2 2026 increased 39% to $116.1 million ($116,060 thousand) from $83.4 million ($83,375 thousand) in Q2 2025. - **Non-GAAP SG&A:** Non-GAAP SG&A expenses increased 34% to $111.7 million from $83.1 million in Q2 2025. - **Research and Development (R&D) Expenses:** R&D expenses in Q2 2026 increased 40% to $51.3 million ($51,301 thousand) from $36.5 million ($36,538 thousand) in Q2 2025. - **Acquired In-Process R&D:** An acquired in-process R&D charge of $1.5 million ($1,500 thousand) was included in Q2 2026, compared to $0 in Q2 2025. ### Operating Profit/Loss - **GAAP Operating Loss:** GAAP loss from operations was -$17.3 million (-$17,267 thousand) in Q2 2026, an improvement from -$22.7 million (-$22,689 thousand) in Q2 2025. Year-to-date GAAP loss from operations was -$37.123 million, compared to -$43.367 million in 2025. - **Non-GAAP Operating Loss:** Non-GAAP loss from operations was -$7.6 million in Q2 2026, compared to -$16.6 million in Q2 2025. Year-to-date Non-GAAP loss from operations was -$18.077 million, compared to -$31.785 million in 2025. ### Net Loss - **GAAP Net Loss:** GAAP net loss was -$18.4 million (-$18,377 thousand), or -$0.31 per diluted share, in Q2 2026, compared to -$19.7 million (-$19,657 thousand), or -$0.34 per diluted share, in Q2 2025. Year-to-date GAAP net loss was -$38.160 million, or -$0.65 per diluted share, compared to -$37.803 million, or -$0.66 per diluted share, in 2025. - **Non-GAAP Net Loss:** Non-GAAP net loss was -$8.3 million, or -$0.14 per diluted share, in Q2 2026, compared to -$13.6 million, or -$0.24 per diluted share, in Q2 2025. Year-to-date Non-GAAP net loss was -$18.745 million, or -$0.32 per diluted share, compared to -$26.221 million, or -$0.46 per diluted share, in 2025. ### Capital Expenditures Capital expenditures were $2.7 million in Q2 2026, an increase of $1.5 million from $1.2 million in Q2 2025. ### Outlook / Guidance Glaukos Corporation has raised its full-year 2026 global consolidated net sales guidance to a range of $680 million to $700 million, an increase from its previous guidance of $620 million to $635 million. This revised guidance considers potential growing contributions from iDose TR, Epioxa, and iStent infinite, while also factoring in potential transient headwinds in the U.S. Corneal Health franchise during Q3 due to the Photrexa to Epioxa transition. The company also acknowledges uncertainties related to MAC’s proposed LCDs for iDose TR, global combo-cataract MIGS competition, and the broader macroeconomic and geopolitical environment. ### Related Stocks - [GKOS.US](https://longbridge.com/en/quote/GKOS.US.md) ## Related News & Research - [Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today](https://longbridge.com/en/news/296936383.md) - [Glaukos (GKOS), Why Is The Story Getting Harder To Ignore?](https://longbridge.com/en/news/296739885.md) - [Glaukos director Gilbert H. Kliman disposes of 2,500 common shares for $475,000](https://longbridge.com/en/news/296547975.md) - [Glaukos management to participate in Wells Fargo Healthcare Conference](https://longbridge.com/en/news/296343630.md) - [Northann amends 8-K to file former auditor LAO Professionals’ letter on resignation](https://longbridge.com/en/news/296825824.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**